Life Science Research

Venture Fund Consortium bases its investment criteria around largest market potential, strong competitive advantage and intellectual property protection potential and the projects ability to "survive" for the long term, especially in the field of life science investments, where it can take many years before a product or service could be brought to market.

Venture Fund Consortium, began its work many years ago, with a focus on taking Eastern European and Asian technology and intellectual property and in transferring it into the US, the UK and other Western European countries and commercializing them there. We quickly learned that it was extremely difficult to negotiate with individuals and organizations in those parts of the world, who did not have a standard understanding of business practices and who believed that commerce and business were inherently evil. There was also a major problem with intellectual property, as a lot of the projects that we identified, were not properly protected, and scientific publication that gave away a large part of the intellectual property into the public domain, was considered more important than proper intellectual property protection and patents. After a number of failed negotiation and intellectual property acquisition attempts, the business model began to change and evolved into a successful business model that the Venture Fund Consortium still uses today.

The Venture Fund Consortium began to focus its efforts on academic and research organizations primarily in the Western World. The intellectual property was very well protected, the scientific community and the administration understood the value of commercialization and the value that our commercialization expertise brings to the project, and over the years the Venture Fund Consortium has continued to work under a very similar model acquiring and developing intellectual property in-house; finding new uses for the technology we acquired and by being able to keep the company going for many years, while continuing to improve the technology and the intellectual property at a fraction of the cost of competition by outsourcing to our overseas facilities.

VFCFAR also specifically focuses on companies that are of great value to our government and to our NGO partners and to humanity, which significantly improves our ability to receive grant funding and other forms of incentives for the companies. VFCFAR has many years of experience working with NGO and with government partners to raise non dilutive capital for our projects, making sure that the company survival rate can exceed regulatory approval, which in the case of life science companies usually takes many years. The number one reason for start up failure in the life science industry is the companies inability to survive long enough to see its products receive FDA approval, and we believe that it is the ability to keep the companies going, that will determine our success both in the world of Life Science and in other fields.